- Home
- INBX vs CLYM Comparison
INBX vs CLYM Comparison
Compare INBX & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBX
- CLYM
- Stock Information
- Founded
- INBX 2010
- CLYM 2018
- Country
- INBX United States
- CLYM United States
- Employees
- INBX N/A
- CLYM N/A
- Industry
- INBX Biotechnology: Pharmaceutical Preparations
- CLYM
- Sector
- INBX Health Care
- CLYM
- Exchange
- INBX Nasdaq
- CLYM NYSE
- Market Cap
- INBX 218.9M
- CLYM 201.7M
- IPO Year
- INBX 2020
- CLYM 2021
- Fundamental
- Price
- INBX $13.92
- CLYM $1.95
- Analyst Decision
- INBX Hold
- CLYM
- Analyst Count
- INBX 1
- CLYM 0
- Target Price
- INBX N/A
- CLYM N/A
- AVG Volume (30 Days)
- INBX 81.4K
- CLYM 264.1K
- Earning Date
- INBX 11-14-2024
- CLYM 11-12-2024
- Dividend Yield
- INBX N/A
- CLYM N/A
- EPS Growth
- INBX N/A
- CLYM N/A
- EPS
- INBX 119.38
- CLYM N/A
- Revenue
- INBX $1,568,000.00
- CLYM N/A
- Revenue This Year
- INBX N/A
- CLYM N/A
- Revenue Next Year
- INBX N/A
- CLYM N/A
- P/E Ratio
- INBX $0.12
- CLYM N/A
- Revenue Growth
- INBX 19.24
- CLYM N/A
- 52 Week Low
- INBX $10.80
- CLYM $1.86
- 52 Week High
- INBX $18.95
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- INBX 38.33
- CLYM N/A
- Support Level
- INBX $14.53
- CLYM N/A
- Resistance Level
- INBX $15.24
- CLYM N/A
- Average True Range (ATR)
- INBX 0.72
- CLYM 0.00
- MACD
- INBX -0.10
- CLYM 0.00
- Stochastic Oscillator
- INBX 19.16
- CLYM 0.00
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.